Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Interest Expenses (2016 - 2025)

United Therapeutics (UTHR) has disclosed Interest Expenses for 17 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • Quarterly Interest Expenses fell 60.76% to $3.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.5 million through Dec 2025, down 54.55% year-over-year, with the annual reading at $19.5 million for FY2025, 54.55% down from the prior year.
  • Interest Expenses hit $3.1 million in Q4 2025 for United Therapeutics, up from $3.0 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $15.6 million in Q3 2023 to a low of $3.0 million in Q3 2025.
  • Historically, Interest Expenses has averaged $8.6 million across 5 years, with a median of $7.6 million in 2024.
  • Biggest five-year swings in Interest Expenses: soared 193.62% in 2023 and later crashed 70.3% in 2025.
  • Year by year, Interest Expenses stood at $4.7 million in 2021, then surged by 161.7% to $12.3 million in 2022, then grew by 22.76% to $15.1 million in 2023, then crashed by 47.68% to $7.9 million in 2024, then crashed by 60.76% to $3.1 million in 2025.
  • Business Quant data shows Interest Expenses for UTHR at $3.1 million in Q4 2025, $3.0 million in Q3 2025, and $7.3 million in Q2 2025.